Business
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET.\nThis event is open access for all investors. Topics will include:\n\n\nAn overview of InMed's pharmaceutical pipeline in Alzheimer's and ocular\n\n\nA discussion of upcoming 2024 milestone in both InMed's pharmaceutical drug development and in BayMedica's health and wellness initiatives\n\n\nAn overview of cannabinoids and their possible role in the treatment of Alzheimer's\n\n\nInterested parties can register for the event at the link below. Replays of the webcast will also be available after the event.\nPLEASE REGISTER HERE\nAbout InMed:InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.\nAbout Water Tower Research:\nWater Tower Research is a shareholder communication and engagement platform powered by senior industry experts with significant Wall Street experience. We create, deliver, and maintain the information flow required to build and preserve relationships with every stakeholder and potential investor. Our foundation is built on Wall Street veterans using open digital distribution strategies that are accessible by everyone. \"Research for the Other 99%™\" opens the door to reach a much broader and diverse set of investors while helping to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com/home.\nInvestor Contact:Colin Clancy\nVice President, Investor Relations\nand Corporate Communications\nT: +1 604 416 0999\nE: cclancy@inmedpharm...